Kamdje AHN, Etet PFS, Vecchio L, Tagne RS, Amvene JM, Muller JM, Krampera M, Lukong KE. New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers. World J Clin Cases 2014; 2(12): 769-786 [PMID: 25516852 DOI: 10.12998/wjcc.v2.i12.769]
Corresponding Author of This Article
Armel Hervé Nwabo Kamdje, PhD, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundere, PO Box 454, Ngaoundere, Cameroon. armel.nwabo@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 16, 2014; 2(12): 769-786 Published online Dec 16, 2014. doi: 10.12998/wjcc.v2.i12.769
New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers
Armel Hervé Nwabo Kamdje, Paul Faustin Seke Etet, Lorella Vecchio, Richard Simo Tagne, Jeremie Mbo Amvene, Jean-Marc Muller, Mauro Krampera, Kiven Erique Lukong
Armel Hervé Nwabo Kamdje, Richard Simo Tagne, Jeremie Mbo Amvene, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundéré, PO Box 454, Ngaoundéré, Cameroon
Paul Faustin Seke Etet, Lorella Vecchio, Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 52571, Saudi Arabia
Jean-Marc Muller, Université de Poitiers, Faculté des Sciences, Pôle Biologie-Santé Bât B36, 1, rue Georges Bonnet-BP633, 86022 Poitiers cedex, France
Mauro Krampera, Department of Medicine, Section of Hematology, Stem Cell Research Laboratory, University of Verona, 37129 Verona, Italy
Kiven Erique Lukong, Department of Biochemistry, College of Medicine, University of Saskatchewan, Saskatoon S7N 5E5, Canada
Author contributions: All authors contributed to this paper.
Correspondence to: Armel Hervé Nwabo Kamdje, PhD, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundere, PO Box 454, Ngaoundere, Cameroon. armel.nwabo@gmail.com
Telephone: +237-90-190421 Fax: +237-22-251747
Received: May 30, 2014 Revised: July 12, 2014 Accepted: September 23, 2014 Published online: December 16, 2014 Processing time: 202 Days and 13.8 Hours
Abstract
Breast cancer is the most frequent female malignancy worldwide. Current strategies in breast cancer therapy, including classical chemotherapy, hormone therapy, and targeted therapies, are usually associated with chemoresistance and serious adverse effects. Advances in our understanding of changes affecting the interactome in advanced and chemoresistant breast tumors have provided novel therapeutic targets, including, cyclin dependent kinases, mammalian target of rapamycin, Notch, Wnt and Shh. Inhibitors of these molecules recently entered clinical trials in mono- and combination therapy in metastatic and chemo-resistant breast cancers. Anticancer epigenetic drugs, mainly histone deacetylase inhibitors and DNA methyltransferase inhibitors, also entered clinical trials. Because of the complexity and heterogeneity of breast cancer, the future in therapy lies in the application of individualized tailored regimens. Emerging therapeutic targets and the implications for personalized-based therapy development in breast cancer are herein discussed.
